Tumor Necrosis Factor Inhibitor Drugs Market by Product, Sales Channel and Application - Global Industry Analysis & Forecast to 2027
Published On : July 2019 Pages : 161 Category: Pharmaceuticals Report Code : HC074470
Tumor Necrosis Factor Inhibitor Drugs Market by Product (Biosimilars, Humira, Cimzia, Enbrel, Simponi/Simponi Aria, Remicade) Sales Channel (Online Pharmacies, Specialty Pharmacies, Hospital Pharmacies) Application (Hidradenitis Suppurativa, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis, Crohn’s Disease, Other Applications) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Tumor Necrosis Factor Inhibitor Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. TNF inhibitors are utilized to stifle the fiery reaction brought about by TNF cytokines and subsequently are utilized for the treatment of provocative and immune system infections, for example, rheumatoid joint inflammation, psoriasis, Crohn's disease, and cancer among others. The job of TNF inhibitors in the treatment of metastatic melanomas and privately progressed delicate tissue sarcomas is under scrutiny.
Drivers and Restraints
The development is anticipated to be driven by new launches of product, promising pipeline, expanding frequency of immune system sicknesses, and a huge ascent in buyer awareness with respect to Tumor Necrosis Factor (TNF).
Regional Insights
Asia Pacific is evaluated to be one of the quickest developing districts, over the gauge time frame. The pattern of biosimilars in the developing markets, for example, China, India, and South Korea, is a key provincial development driver.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Merck & co., Inc.
- AbbVie Inc.
- Pfizer, Inc.
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- Novartis International AG
- UCB S.A.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Tumor Necrosis Factor Inhibitor Drugs Market, By Product, Estimates and Forecast, 2017-2027 ($Million)
o Biosimilars
o Humira
o Cimzia
o Enbrel
o Simponi/Simponi Aria
o Remicade
o Tumor Necrosis Factor Inhibitor Drugs Market, By Sales Channel, Estimates and Forecast, 2017-2027 ($Million)
o Online Pharmacies
o Specialty Pharmacies
o Hospital Pharmacies
o Tumor Necrosis Factor Inhibitor Drugs Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Hidradenitis Suppurativa
o Rheumatoid Arthritis
o Juvenile Idiopathic Arthritis
o Psoriasis
o Ankylosing Spondylitis
o Psoriatic Arthritis
o Ulcerative Colitis
o Crohn’s Disease
o Other Applications
o Tumor Necrosis Factor Inhibitor Drugs Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Merck & co., Inc.
o AbbVie Inc.
o Pfizer, Inc.
o Amgen Inc.
o Johnson & Johnson Services, Inc.
o Novartis International AG
o UCB S.A.
o Tumor Necrosis Factor Inhibitor Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Tumor Necrosis Factor Inhibitor Drugs Market, By Country
o U.S. Tumor Necrosis Factor Inhibitor Drugs Market
o Canada Tumor Necrosis Factor Inhibitor Drugs Market
o Mexico Tumor Necrosis Factor Inhibitor Drugs Market
o Europe
§ Europe Tumor Necrosis Factor Inhibitor Drugs Market, By Country
o Germany Tumor Necrosis Factor Inhibitor Drugs Market
o UK Tumor Necrosis Factor Inhibitor Drugs Market
o France Tumor Necrosis Factor Inhibitor Drugs Market
o Russia Tumor Necrosis Factor Inhibitor Drugs Market
o Italy Tumor Necrosis Factor Inhibitor Drugs Market
o Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market
o Asia-Pacific
§ Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, By Country
o China Tumor Necrosis Factor Inhibitor Drugs Market
o Japan Tumor Necrosis Factor Inhibitor Drugs Market
o South Korea Tumor Necrosis Factor Inhibitor Drugs Market
o India Tumor Necrosis Factor Inhibitor Drugs Market
o Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Market
o Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market
o South America
§ South America Tumor Necrosis Factor Inhibitor Drugs Market, By Country
o Brazil Tumor Necrosis Factor Inhibitor Drugs Market
o Argentina Tumor Necrosis Factor Inhibitor Drugs Market
o Columbia Tumor Necrosis Factor Inhibitor Drugs Market
o Rest of South America Tumor Necrosis Factor Inhibitor Drugs Market
o Middle East and Africa
§ Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market, By Country
o Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market
o UAE Tumor Necrosis Factor Inhibitor Drugs Market
o Egypt Tumor Necrosis Factor Inhibitor Drugs Market
o Nigeria Tumor Necrosis Factor Inhibitor Drugs Market
o South Africa Tumor Necrosis Factor Inhibitor Drugs Market
o Rest of MEA Tumor Necrosis Factor Inhibitor Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Tumor Necrosis Factor Inhibitor Drugs Market, By Product
5.1. Introduction
5.2. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Market Share by Product (2017-2027)
5.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Revenue Share by Product (2017-2027)
5.3. Biosimilars
5.3.1. Global Biosimilars Revenue and Growth Rate (2017-2027)
5.4. Humira
5.4.1. Global Humira Revenue and Growth Rate (2017-2027)
5.5. Cimzia
5.5.1. Global Cimzia Revenue and Growth Rate (2017-2027)
5.6. Enbrel
5.6.1. Global Enbrel Revenue and Growth Rate (2017-2027)
5.7. Simponi/Simponi Aria
5.7.1. Global Simponi/Simponi Aria Revenue and Growth Rate (2017-2027)
5.8. Remicade
5.8.1. Global Remicade Revenue and Growth Rate (2017-2027)
6. Tumor Necrosis Factor Inhibitor Drugs Market, By Sales Channel
6.1. Introduction
6.2. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Market Share by Sales Channel (2017-2027)
6.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Revenue Share by Sales Channel (2017-2027)
6.3. Online Pharmacies
6.3.1. Global Online Pharmacies Revenue and Growth Rate (2017-2027)
6.4. Specialty Pharmacies
6.4.1. Global Specialty Pharmacies Revenue and Growth Rate (2017-2027)
6.5. Hospital Pharmacies
6.5.1. Global Hospital Pharmacies Revenue and Growth Rate (2017-2027)
7. Tumor Necrosis Factor Inhibitor Drugs Market, By Application
7.1. Introduction
7.2. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Market Share by Application (2017-2027)
7.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Revenue Share by Application (2017-2027)
7.3. Hidradenitis Suppurativa
7.3.1. Global Hidradenitis Suppurativa Revenue and Growth Rate (2017-2027)
7.4. Rheumatoid Arthritis
7.4.1. Global Rheumatoid Arthritis Revenue and Growth Rate (2017-2027)
7.5. Juvenile Idiopathic Arthritis
7.5.1. Global Juvenile Idiopathic Arthritis Revenue and Growth Rate (2017-2027)
7.6. Psoriasis
7.6.1. Global Psoriasis Revenue and Growth Rate (2017-2027)
7.7. Ankylosing Spondylitis
7.7.1. Global Ankylosing Spondylitis Revenue and Growth Rate (2017-2027)
7.8. Psoriatic Arthritis
7.8.1. Global Psoriatic Arthritis Revenue and Growth Rate (2017-2027)
7.9. Ulcerative Colitis
7.9.1. Global Ulcerative Colitis Revenue and Growth Rate (2017-2027)
7.10. Crohn’s Disease
7.10.1. Global Crohn’s Disease Revenue and Growth Rate (2017-2027)
7.11. Other Applications
7.11.1. Global Other Applications Revenue and Growth Rate (2017-2027)
8. Tumor Necrosis Factor Inhibitor Drugs Market, By Region
8.1. Introduction
8.2. Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Market Share by Regions
8.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Revenue by Regions (2017-2027)
8.3. North America Tumor Necrosis Factor Inhibitor Drugs by Countries
8.3.1. North America Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2027)
8.3.2. North America Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Tumor Necrosis Factor Inhibitor Drugs by Countries
8.4.1. Europe Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2027)
8.4.2. Europe Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs by Countries
8.5.1. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Tumor Necrosis Factor Inhibitor Drugs by Countries
8.6.1. South America Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2027)
8.6.2. South America Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs by Countries
8.7.1. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Merck & co., Inc.
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. AbbVie Inc.
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. Pfizer, Inc.
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Amgen Inc.
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. Johnson & Johnson Services, Inc.
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
9.6. Novartis International AG
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Financial Overview
9.7. UCB S.A.
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Financial Overview
10. Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.1. Global Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Tumor Necrosis Factor Inhibitor Drugs Market Forecast by Regions (2017-2027)
10.2.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.1.1. United States Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.1.2. Canada Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.1.3. Mexico Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2. Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2.1. Germany Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2.2. France Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2.3. UK Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2.4. Russia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2.5. Italy Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3.1. China Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3.2. Japan Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3.3. Korea Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3.4. India Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.4. South America Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.4.1. Brazil Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.4.2. Argentina Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.4.3. Columbia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.4.4. Rest of South America Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.3. Egypt Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.4. Nigeria Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.5. South Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.6. Turkey Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2017-2027)
10.3. Tumor Necrosis Factor Inhibitor Drugs Market Forecast by Product (2017-2027)
10.3.1. Tumor Necrosis Factor Inhibitor Drugs Forecast by Product (2017-2027)
10.3.2. Tumor Necrosis Factor Inhibitor Drugs Market Share Forecast by Product (2017-2027)
10.4. Tumor Necrosis Factor Inhibitor Drugs Market Forecast by Sales Channel (2017-2027)
10.4.1. Tumor Necrosis Factor Inhibitor Drugs Forecast by Sales Channel (2017-2027)
10.4.2. Tumor Necrosis Factor Inhibitor Drugs Market Share Forecast by Sales Channel (2017-2027)
10.5. Tumor Necrosis Factor Inhibitor Drugs Market Forecast by Application (2017-2027)
10.5.1. Tumor Necrosis Factor Inhibitor Drugs Forecast by Application (2017-2027)
10.5.2. Tumor Necrosis Factor Inhibitor Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Revenue Share by Product (2017-2018)
Figure Global Biosimilars Revenue and Growth Rate (2017-2018)
Figure Global Humira Revenue and Growth Rate (2017-2018)
Figure Global Cimzia Revenue and Growth Rate (2017-2018)
Figure Global Enbrel Revenue and Growth Rate (2017-2018)
Figure Global Simponi/Simponi Aria Revenue and Growth Rate (2017-2018)
Figure Global Remicade Revenue and Growth Rate (2017-2018)
Table Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Revenue Share by Sales Channel (2017-2018)
Figure Global Online Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global Specialty Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global Hospital Pharmacies Revenue and Growth Rate (2017-2018)
Table Global Tumor Necrosis Factor Inhibitor Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Hidradenitis Suppurativa Revenue and Growth Rate (2017-2018)
Figure Global Rheumatoid Arthritis Revenue and Growth Rate (2017-2018)
Figure Global Juvenile Idiopathic Arthritis Revenue and Growth Rate (2017-2018)
Figure Global Psoriasis Revenue and Growth Rate (2017-2018)
Figure Global Ankylosing Spondylitis Revenue and Growth Rate (2017-2018)
Figure Global Psoriatic Arthritis Revenue and Growth Rate (2017-2018)
Figure Global Ulcerative Colitis Revenue and Growth Rate (2017-2018)
Figure Global Crohn’s Disease Revenue and Growth Rate (2017-2018)
Figure Global Other Applications Revenue and Growth Rate (2017-2018)
Table Global Tumor Necrosis Factor Inhibitor Drugs Revenue by Regions (2017-2018)
Figure North America Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure North America Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2018)
Figure North America Tumor Necrosis Factor Inhibitor Drugs by Countries (2017-2018)
Figure North America Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure United States Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Canada Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Mexico Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Europe Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Tumor Necrosis Factor Inhibitor Drugs by Countries (2017-2018)
Figure Europe Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Germany Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure France Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure UK Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Russia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Italy Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs by Countries (2017-2018)
Figure Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure China Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Japan Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Korea Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure India Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure South America Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2018)
Figure South America Tumor Necrosis Factor Inhibitor Drugs by Countries (2017-2018)
Figure South America Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Brazil Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Argentina Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Columbia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Rest of South America Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs by Countries (2017-2018)
Figure Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Egypt Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Nigeria Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure South Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Turkey Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck & co., Inc. Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Table AbbVie Inc. Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Table Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Table Amgen Inc. Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Table Johnson & Johnson Services, Inc. Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Table Novartis International AG Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Table UCB S.A. Tumor Necrosis Factor Inhibitor Drugs Financial Overview
Figure Global Tumor Necrosis Factor Inhibitor Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Tumor Necrosis Factor Inhibitor Drugs Market Forecast by Regions (2018-2025)
Figure North America Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure United States Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Canada Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Mexico Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Germany Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure France Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure UK Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Russia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Italy Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure China Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Japan Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Korea Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure India Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Southeast Asia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure South America Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Brazil Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Argentina Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Columbia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Rest of South America Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Egypt Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Nigeria Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure South Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Turkey Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecast (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Forecast by Product (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Market Share Forecast by Product (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Forecast by Product (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Forecast by Sales Channel (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Market Share Forecast by Sales Channel (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Forecast by Sales Channel (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Forecast by Application (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Market Share Forecast by Application (2018-2025)
Figure Global Tumor Necrosis Factor Inhibitor Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|